to intravitreal bevacizumab in hypertensive retinopathy
Sir, We read with interest the case report [1] on the resolution of bilateral subfoveal fluid and disc edema due to hypertensive retinopathy (HTNR) after unilateral intravitreal bevacizumab. We want to discuss few points. As the primary cause of HTNR is hypertension, the adequate control of hypertension is the most important intervention. Without the adequate control of BP, any intervention including intravitreal anti-vascular endothelial growth factor (VEGF) agents may not be considered. Though bevacizumab has been considered as a "wonder drug," it carries a rare but devastating risk of blindness due to endophthalmitis. [2] However, in the clinical setting even after control of hypertension, the subfoveal fluid may not resolve and the patient may want earlier visual rehabilitation. Salman [3] used intravitreal bevacizumab in 12 cases of persistent HTNR despite control of hypertension for 1 month and noted stabilization and improvement of vision in all cases. This paper [1] also adds to the evidence [4, 5] that anti-VEGF agents may be helpful in HTNR. The exact role of anti-VEGF agents in HTNR needs further exploration, but these agents may add to the armamentarium to treat the cases of HTNR with subfoveal fluid which do not resolve despite good systemic control.
